{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T18:07:52Z","timestamp":1792951672100,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,4,25]],"date-time":"2016-04-25T00:00:00Z","timestamp":1461542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clgc.2016.04.011","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T06:59:07Z","timestamp":1461999547000},"page":"406-414","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials"],"prefix":"10.1016","volume":"14","author":[{"given":"Petri","family":"Bono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istvan","family":"Bodrogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Hutson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Escudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Figlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Ravaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brechenmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinjune","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Voi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Grunwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2016.04.011_bib1","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1002\/cncr.25219","article-title":"Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors","volume":"116","author":"Motzer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2016.04.011_bib2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ejca.2011.06.054","article-title":"An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy","volume":"48","author":"Gr\u00fcnwald","year":"2012","journal-title":"Eur J Cancer"},{"issue":"suppl 2","key":"10.1016\/j.clgc.2016.04.011_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1634\/theoncologist.2011-S2-32","article-title":"Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies","volume":"16","author":"Ravaud","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2016.04.011_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/nrneph.2015.15","article-title":"Renal effects of targeted anticancer therapies","volume":"11","author":"Porta","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.clgc.2016.04.011_bib5","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ctrv.2012.04.009","article-title":"Therapy management with sunitinib in patients with metastatic renal cell carcinoma: key\u00a0concepts and the impact of clinical biomarkers","volume":"39","author":"Castellano","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clgc.2016.04.011_bib6","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1158\/1535-7163.MCT-10-0873","article-title":"Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers","volume":"9","author":"Pal","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2016.04.011_bib7","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","article-title":"Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker","volume":"30","author":"Robinson","year":"2010","journal-title":"Semin Nephrol"},{"issue":"suppl 15","key":"10.1016\/j.clgc.2016.04.011_bib8","article-title":"Association of diastolic blood pressure (dBP)\u00a0\u226590\u00a0mm Hg with overall survival (OS) in patients treated with axitinib (AG- 013736)","volume":"26","author":"Rini","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.clgc.2016.04.011_bib9","article-title":"Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC)","volume":"27","author":"Rixe","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 8","key":"10.1016\/j.clgc.2016.04.011_bib10","first-page":"viii284","article-title":"Axitinib pharmacokinetics and blood pressure changes in front-line metastatic renal cell carcinoma (RCC) patients","volume":"21","author":"Fishman","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.04.011_bib11","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.04.011_bib12","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma","volume":"50","author":"Bono","year":"2011","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2016.04.011_bib13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000329933","article-title":"Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines","volume":"35","author":"Szmit","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.clgc.2016.04.011_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/jnci\/djr128","article-title":"Hypertension is a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"Rini","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.04.011_bib15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/jnci\/djr328","article-title":"Re: hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"103","author":"van den Meiracker","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2016.04.011_bib16","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2016.04.011_bib17","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1158\/1078-0432.CCR-11-3137","article-title":"Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus","volume":"18","author":"Lee","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2016.04.011_bib18","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.ejca.2011.02.014","article-title":"Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma","volume":"47","author":"Porta","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2016.04.011_bib19","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.2217\/fon.15.241","article-title":"REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis","volume":"11","author":"Bracarda","year":"2015","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2016.04.011_bib20","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1200\/JCO.2011.39.7356","article-title":"Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway","volume":"30","author":"Busaidy","year":"2012","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731630101X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876731630101X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:25:19Z","timestamp":1761564319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876731630101X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S155876731630101X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2016.04.011","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2016.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}